1. Home
  2. PMT vs MLYS Comparison

PMT vs MLYS Comparison

Compare PMT & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PMT
  • MLYS
  • Stock Information
  • Founded
  • PMT 2009
  • MLYS 2019
  • Country
  • PMT United States
  • MLYS United States
  • Employees
  • PMT N/A
  • MLYS N/A
  • Industry
  • PMT Real Estate Investment Trusts
  • MLYS Biotechnology: Pharmaceutical Preparations
  • Sector
  • PMT Real Estate
  • MLYS Health Care
  • Exchange
  • PMT Nasdaq
  • MLYS Nasdaq
  • Market Cap
  • PMT 1.1B
  • MLYS 893.0M
  • IPO Year
  • PMT 2009
  • MLYS 2023
  • Fundamental
  • Price
  • PMT $12.75
  • MLYS $14.65
  • Analyst Decision
  • PMT Buy
  • MLYS Strong Buy
  • Analyst Count
  • PMT 9
  • MLYS 3
  • Target Price
  • PMT $14.75
  • MLYS $33.00
  • AVG Volume (30 Days)
  • PMT 998.1K
  • MLYS 650.3K
  • Earning Date
  • PMT 04-22-2025
  • MLYS 05-12-2025
  • Dividend Yield
  • PMT 12.58%
  • MLYS N/A
  • EPS Growth
  • PMT N/A
  • MLYS N/A
  • EPS
  • PMT 0.86
  • MLYS N/A
  • Revenue
  • PMT $591,251,000.00
  • MLYS N/A
  • Revenue This Year
  • PMT N/A
  • MLYS N/A
  • Revenue Next Year
  • PMT $1.13
  • MLYS N/A
  • P/E Ratio
  • PMT $14.80
  • MLYS N/A
  • Revenue Growth
  • PMT N/A
  • MLYS N/A
  • 52 Week Low
  • PMT $11.77
  • MLYS $8.24
  • 52 Week High
  • PMT $15.22
  • MLYS $18.38
  • Technical
  • Relative Strength Index (RSI)
  • PMT 45.25
  • MLYS 53.36
  • Support Level
  • PMT $12.59
  • MLYS $14.03
  • Resistance Level
  • PMT $12.89
  • MLYS $15.79
  • Average True Range (ATR)
  • PMT 0.30
  • MLYS 0.99
  • MACD
  • PMT 0.07
  • MLYS 0.10
  • Stochastic Oscillator
  • PMT 62.60
  • MLYS 57.57

About PMT PennyMac Mortgage Investment Trust of Beneficial Interest

PennyMac Mortgage Investment Trust is a specialty finance company that invests primarily in residential mortgage loans and mortgage-related assets. The company's operations include activities such as the production and servicing of financial securities based on residential loans and the pooling and reselling of high-credit-quality mortgages. The company operates through three segments: correspondent production, credit-sensitive strategies, interest-rate-sensitive strategies. The Credit sensitive strategies segment generates income via investments in CRT arrangements, subordinate MBS, distressed loans, and real estate.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: